 GlaxoSmithKline plc NYSE: GSK and Vir Biotechnology Inc NASDAQ: VIR have announced an update to bioRxiv, a preprint server, with preclinical data for sotrovimab, COVID-19 targeting monoclonal antibody. The data demonstrated that sotrovimab retains activity against key mutations of the new Omicron SARS-CoV-2 variant, including those found in the binding site of sotrovimab. 